The Immune Microenvironment of Myeloma

被引:38
作者
Noonan, Kimberly [1 ]
Borrello, Ivan [1 ]
机构
[1] Johns Hopkins Univ, Dept Oncol, 1650 Orleans St CRB-1,Rm 453, Baltimore, MD 21231 USA
关键词
Bone marrow microenvironment; Immunology; T cells; Osteoclasts;
D O I
10.1007/s12307-011-0086-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bone marrow (BM) is the site of disease in myeloma and possesses unique immune characteristics involved in the pathobiology of the disease. Interactions of plasma cells with stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells make up the unique bone marrow milieu that mediates myeloma disease progression. Independently or through a complex network of interactions these cells impart immune changes leading to immune evasion and disease progression. The critical role of these factors in disease progression has led to the intense development of therapeutic strategies aimed at either disrupting the immune mechanisms mediating disease progression or augmenting those with anti-tumor benefits. This review discusses the major contributors of immunity in the bone marrow microenvironment, their interactions, and mechanisms whereby immune modulation can be translated into therapies with anti-myeloma efficacy.
引用
收藏
页码:313 / 323
页数:11
相关论文
共 122 条
[1]   Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Shioyasono, A ;
Moriyama, K ;
Hashimoto, T ;
Kido, S ;
Oshima, T ;
Shibata, H ;
Ozaki, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2004, 104 (08) :2484-2491
[2]   Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma [J].
Abildgaard, N ;
Glerup, H ;
Rungby, J ;
Bendix-Hansen, K ;
Kassem, M ;
Brixen, K ;
Heickendorff, L ;
Nielsen, JL ;
Eriksen, EF .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 64 (02) :121-129
[3]   Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis [J].
Agarwal, Jasmin Roya ;
Matsui, William .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (02) :116-120
[4]   Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 [J].
Anderson, G ;
Gries, M ;
Kurihara, N ;
Honjo, T ;
Anderson, J ;
Donnenberg, V ;
Donnenberg, A ;
Ghobrial, I ;
Mapara, MY ;
Stirling, D ;
Roodman, D ;
Lentzsch, S .
BLOOD, 2006, 107 (08) :3098-3105
[5]  
ANDERSON KC, 1989, BLOOD, V73, P1915
[6]  
[Anonymous], 2004, BLOOD, V104, p1a
[7]  
BAKKUS MHC, 1992, BLOOD, V80, P2326
[8]  
Barber A, 2011, GENE THER
[9]   Molecular pathogenesis and a consequent classification of multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6333-6338
[10]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238